Skip to main content

NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001426332

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q3 2023 vs. Q2 2023

How the institutions holding NGM Biopharmaceuticals Inc changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of NGM: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders10695−11
Shares48.0M47.1M−887.8K (−1.8%)
Value$124.4M$50.6M−$73.8M (−59.3%)

New holders (12)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to NGM in Q3 2023
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC275,000$294.3K0.01%
Squarepoint Ops LLC139,659$149.4K0.00%
Cubist Systematic Strategies, LLC34,089$36.5K0.00%
Pale Fire Capital SE33,800$36.2K0.00%
Point72 Middle East FZE28,771$30.8K0.00%
SG Americas Securities, LLC21,975$24.0K0.00%
UBS Group AG22,180$23.7K0.00%
Carson Advisory Inc.15,850$17.0K0.01%
Virtu Financial LLC10,754$12.0K0.00%
Engineers Gate Manager LP11,029$11.8K0.00%
Capital Advisors, Ltd. LLC630$1.00K0.00%
Group One Trading, L.P.452$4840.00%

Sold out (23)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q2 2023 and filed for Q3 2023 without it.